1 Result: CureVac
CureVac's Patent Litigation Moves to Virginia, Ambrx Biopharma Receives Overweight Rating, Legend Biotech Gets Price Target Boost
May 19th, 2023
CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachuset. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Countdown to Earnings: Keysight, KE Holdings, CAVA on Deck
May 17th, 2026FAA Releases Bold, New Air Traffic Controller Hiring Plan
May 15th, 2026Miami Legends Spotlight Coaching Staff Ahead of 2026 Season
May 14th, 2026




Member Login